- Effectiveness and timeliness of R&D in Life Sciences;
These graphics demonstrate the decline in R&D returns among biopharmaceuticals companies. In general, it means, that for biopharmaceuticals companies become harder recoup their investment in R&D. A natural decrease in targets for development leads decreasing in demand for products and leads to a complication of the development process itself, and this in turn leads to a more expensive process and a decrease in demand. Besides, tightening regulation in the direction of personalized medicine forces companies to select more specific targets and active substances.
- Processing high amount of data and making useful conclusions;
The development of information convert technologies and technologies, in general, have enabled scientists to generate and collect more information. But these effects problems with the store, safe, support and manage data. In this huge flow of information lost earlier data, which can be very important for research. In some cases, the processing of data is more expensive than other parts of research. Besides, increasing the workload of scientists may lower the quality of research. It potentially decreases the level of trust in researches.
Business issues
- Complex estimation of company for effectiveness venture investments;
It is a well-known fact that only a small part of new bird companies and startups succeed. Investors who invest money in them and hoping to grow unicorns, very rarely hit the target. They are forced to hide their losses of a dozen unsuccessful investments by little ones that achieve success. The root of the problem is that investors often do not fully verify the dozens of proposals coming every day and even if they do it, they are limited by only one plane of view, most often financial.
- Availability of complex analytical research of Life Sciences industries;
R&D companies, startups, scaleups have one important feature. Their success greatly depends on the technology the company use. Only focusing on financial marks from time to time leads to big failures, remember Theranos. In general meter, only one plane view leads to stable losses and deviations from the desired result. The main cause of such results is the absence of a multiview analysis of companies, which must consider such important aspects as science (technology), legacy, and even social aspects.
